In addition, type of pathogenic variant (BRCA1 or BRCA2) may play a role in decision making [49], as BC lifetime risks are higher for BRCA1 PV carriers [1] - a factor not considered in our analyses. This evidence concerns the gene BRCA1 and breast cancer.